Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nanjing Medical Focuses On Medical Trust

This article was originally published in PharmAsia News

Executive Summary

Nanjing Medical Co. Ltd. (NMC) and Nanjing Medical Group have transferred 66 percent of their combined share in NMC Baixin Pharmacy Co., Ltd. to subsidiary Nanjing Pharmaceutical Co., Ltd. The move seeks to consolidate resources for an integrated procurement and supply chain, enabling Nanjing Medical to maximize its business network and increase sales. NMC is also selling out its 30 percent share in Nanjing MeiRui Pharma Co. Ltd. to the latter's U.S. parent company Cal-Nan Horizon Quest, Inc. Analysts believe the divestment allows NMC to focus on its core business of medical trust. The company aims to increase its trust business from the current 500 million yuan to 1 billion yuan in 2008. (Click here for more - Chinese Language)

You may also be interested in...

Alzheimer’s Drug & Dermatitis JAK inhibitor Among New EU Filings

Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.

SynOx Seeks Solution For TGCT With Roche Antibody

The UK's Celleron has attracted a "blue chip suite of investors" to an Irish-domiciled spin-off based on the potential of Roche-developed emactuzumab for TGCT, a debilitating orphan disease that causes joint damage and has limited clinical options.

Oxford/AstraZeneca Vaccine Shows 70% Efficacy As Company Prepares Approval Filings

Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts